نتایج جستجو برای: her2 antigen

تعداد نتایج: 214094  

Journal: :Journal of innovative optical health sciences 2009
Robabeh Rezaeipoor Renu John Steven G Adie Eric J Chaney Marina Marjanovic Amy L Oldenburg Stephanie A Rinne Stephen A Boppart

In this study, we report the fabrication of engineered iron oxide magnetic nanoparticles (MNPs) functionalized with anti-human epidermal growth factor receptor type 2 (HER2) antibody to target the tumor antigen HER2. The Fc-directed conjugation of antibodies to the MNPs aids their efficient immunospecific targeting through free Fab portions. The directional specificity of conjugation was verifi...

2017
Sayyed Nilofar Danishmalik Si-Hyeong Lee Jeong-Im Sin

In the CT26/HER2 and 4T1.2/HER2 tumor models, CT26/HER2 cells form tumors that continue to grow, whereas 4T1.2/HER2 cells form tumors that eventually regress. Here, we investigated the differences in the behaviors of these two cell lines. When immune cells from 4T1.2/HER2 tumor-bearing animals were stimulated with HER2 class I peptides, they displayed a 2-fold increase in IFN-γ levels, in respo...

2015
Kin-Mei Leung Sarah Batey Robert Rowlands Samine J Isaac Phil Jones Victoria Drewett Joana Carvalho Miguel Gaspar Sarah Weller Melanie Medcalf Mateusz M Wydro Robert Pegram Geert C Mudde Anton Bauer Kevin Moulder Max Woisetschläger Mihriban Tuna John S Haurum Haijun Sun

FS102 is a HER2-specific Fcab (Fc fragment with antigen binding), which binds HER2 with high affinity and recognizes an epitope that does not overlap with those of trastuzumab or pertuzumab. In tumor cells that express high levels of HER2, FS102 caused profound HER2 internalization and degradation leading to tumor cell apoptosis. The antitumor effect of FS102 in patient-derived xenografts (PDXs...

2016
Sebastian P. Haen Benjamin J. Schmiedel Kathrin Rothfelder Bastian J. Schmied Truong-Minh Dang Nora Mirza Robert Möhle Lothar Kanz Wichard Vogel Helmut R. Salih

The epidermal growth factor receptor HER2/neu is expressed on various cancers and represents a negative prognostic marker, but is also a target for the therapeutic monoclonal antibody Trastuzumab. In about 30% of cases, HER2/neu is expressed on acute lymphoblastic leukemia (ALL) cells and was proposed to be associated with a deleterious prognosis. Here we evaluated clinical data from 65 ALL pat...

2015
Carmen S. M. Yong Janelle Sharkey Belinda Duscio Ben Venville Wei-Zen Wei Richard F. Jones Clare Y. Slaney Gisela Mir Arnau Anthony T. Papenfuss Jan Schröder Phillip K. Darcy Michael H. Kershaw John P. Lydon

The development of antigen-targeted therapeutics is dependent on the preferential expression of tumor-associated antigens (TAA) at targetable levels on the tumor. Tumor-associated antigens can be generated de novo or can arise from altered expression of normal basal proteins, such as the up-regulation of human epidermal growth factor receptor 2 (Her2/ErbB2). To properly assess the development o...

2013
Su He Wang Lin Lu Yongyi Fan Max S. Wicha Zhengyi Cao Alfred E. Chang Jian-chuan Xia James R. Baker Jr. Qiao Li

HER2 is an oncogenic tumor-associated antigen overexpressed in 20-25% of breast cancers, which is associated with increased invasion, metastasis of the disease and resistance to therapy. Recent studies have further shown that HER2 can increase the population of breast cancer stem cells (BCSCs). However, there is currently no in vivo model for the study of HER2(+) BCSCs. In this study, we charac...

Journal: :International journal of molecular medicine 2007
Marc-André Fortin Anna Orlova Per-Uno Malmström Vladimir Tolmachev

The direct instillation of radiolabelled conjugates in the urinary bladder is a promising path for the treatment of bladder carcinoma. The targeting of HER2/neu receptors expressed on the surface of many bladder carcinoma cells shows potential to be developed as a therapeutic strategy, and patients identified with a high risk of progression may benefit from adjuvant targeted radionuclide therap...

2014
Dowdy Jackson John Atkinson Claudia I. Guevara Chunying Zhang Vladimir Kery Sung-Ju Moon Cyrus Virata Peng Yang Christine Lowe Jason Pinkstaff Ho Cho Nick Knudsen Anthony Manibusan Feng Tian Ying Sun Yingchun Lu Aaron Sellers Xiao-Chi Jia Ingrid Joseph Banmeet Anand Kendall Morrison Daniel S. Pereira David Stover

Antibody drug conjugates (ADCs) are monoclonal antibodies designed to deliver a cytotoxic drug selectively to antigen expressing cells. Several components of an ADC including the selection of the antibody, the linker, the cytotoxic drug payload and the site of attachment used to attach the drug to the antibody are critical to the activity and development of the ADC. The cytotoxic drugs or paylo...

Journal: :Cancer research 1998
X G Gu M Schmitt A Hiasa Y Nagata H Ikeda Y Sasaki K Akiyoshi J Sunamoto H Nakamura K Kuribayashi H Shiku

To elicit specific cellular immune responses against cancer, the development of efficient devices to deliver tumor antigen peptides to the MHC class I pathway constitutes a central issue. We report here a novel formula of hydrophobized polysaccharide nanoparticles, which can deliver a HER2 oncoprotein containing an epitope peptide to the MHC class I pathway. A protein consisting of the 147 amin...

2013
SADAYUKI KAWAI SHUNSUKE KATO HIROO IMAI YOSHINARI OKADA CHIKASHI ISHIOKA

Lewis Y (LeY) antigen is an oligosaccharide that is highly expressed at the cell surface in various human cancers. Increased LeY expression activates epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) and promotes cell proliferation in EGFR-overexpressing cells. However, the effect of downregulation of LeY ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید